Johannes P D Schultheiss

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Patients With Inflammatory Bowel Disease

Top Venues

Digestive diseases and sciences

Inflammatory bowel diseases

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Femke M Prins, Iwan J Hidding, Marjolein A Y Klaassen, Valerie Collij, Johannes P D Schultheiss, Werna T C Uniken Venema, Amber Bangma, Jurne B Aardema, Bernadien H Jansen, Wout G N Mares, Ben J M Witteman, Eleonora A M Festen, Gerard Dijkstra, Marijn C Visschedijk, Herma H Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K Weersma
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease. Gut microbes 16 (1) (2024)
Femke M Prins, Iwan J Hidding, Marjolein A Y Klaassen, Valerie Collij, Johannes P D Schultheiss, Werna T C Uniken Venema, Amber Bangma, Jurne B Aardema, Bernadien H Jansen, Wout G N Mares, Ben J M Witteman, Eleonora A M Festen, Gerard Dijkstra, Marijn C Visschedijk, Herma H Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K Weersma
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease. Gut microbes 16 (1) (2024)
Femke M Prins, Iwan J Hidding, Marjolein A Y Klaassen, Valerie Collij, Johannes P D Schultheiss, Werna T C Uniken Venema, Amber Bangma, Jurne B Aardema, Bernadien H Jansen, Wout G N Mares, Ben J M Witteman, Eleonora A M Festen, Gerard Dijkstra, Marijn C Visschedijk, Herma H Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K Weersma
Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease. Gut microbes 16 (1) (2024)
Shaden Mahmmod, Johannes P D Schultheiss, Ad A van Bodegraven, Gerard Dijkstra, Lennard P L Gilissen, Frank Hoentjen, Maurice W M D Lutgens, Nofel Mahmmod, Andrea E van der Meulen-de Jong, Lisa J T Smits, Adriaan C I T L Tan, Bas Oldenburg, Herma H Fidder
Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflammatory bowel diseases 27 (12) (2022)
Johannes P D Schultheiss, Sandra Altena, Max R Clevers, Dominique Baas, Bindia Jharap, Herma H Fidder
Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container. Digestive diseases and sciences 66 (5) (2020)
Johannes P D Schultheiss, Eelco C Brand, Evert Lamers, Willemijn C M van den Berg, Fiona D M van Schaik, Bas Oldenburg, Herma H Fidder
Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Alimentary pharmacology & therapeutics 50 (4) (2019)